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Intellectual disability affects about 1 million people in England.
People with intellectual disability are more likely to develop a
mental disorder and often have multimorbity.1 Appropriate drug
treatment of mental illness is important, but recent evidence
confirms an over-reliance on psychotropic drugs, particularly
antipsychotics, for challenging behaviour when no mental illness
has been recorded. Such use is off-licence and unsupported by
empirical evidence.2 Overuse of medication is concerning as
people with intellectual disability are more sensitive to unwanted
side effects3 and often lack capacity to consent to treatment.
Safe and appropriate use of psychotropic drugs has become a
priority for people with intellectual disability, their care givers,
and services after revelations of shocking abuse of patient trust
and safety, prompting the UK government to review care for
this group of patients with complex needs.4 The serious and
systemic failings identified by the review galvanised clinicians
across primary and secondary care, and an NHS policy drive,
“Stopping over-medication of people with learning disabilities”
(STOMP), now entering its second year, aims to ensure the best
use of psychotropic drugs. Although the STOMP campaign has
kept the issue alive, it is yet to effect real change and there
remains much scope for improving prescribing of psychotropic
drugs for people with intellectual disability.
It is often possible to reduce or discontinue antipsychotic drugs
in people who have been prescribed them long term,5 but there
are associated risks, including unmasking symptoms of mental
disorder, withdrawal reactions, and deteriorations in behaviour.6
Barriers to psychotropic withdrawal include infrequent or
ineffective drug reviews, lack of confidence or motivation
among general and specialist practitioners, and poor access to
specialist psychiatrists or pharmacists to advise on and oversee
medication changes. Other important factors in the inappropriate
maintenance of psychotropic drugs for challenging behaviour
are the lack of supporting evidence for interventions to treat this
behaviour and the inconsistent and patchy implementation of
alternatives to medication.
Predictors of successful reduction of psychotropic drugs
prescribed for challenging behaviour in people with intellectual
disability have not been reliably identified, and new research
into the risks and potential benefits of using these drugs for
challenging behaviour has not been forthcoming.6
A deprescribing algorithm might be one way of changing
practice at scale, but any algorithm must be sufficiently flexible
to accommodate the considerable heterogeneity in this patient
group. Excessive focus on reducing medication might be
discriminatory, for example, if it denies people with intellectual
disability appropriate treatment for mental illness.
A pragmatic approach is needed to optimise medication. Within
this framework, medication is not viewed as inherently good or
bad, but its advantages and disadvantages are considered in
relation to an individual’s clinical needs, preferences, and life
circumstances. People with intellectual disability and their
families report feeling deprived of options, excluded from
decision making processes, and finding it difficult to ask for
more information about psychotropic drugs.
Shared decision making is central to optimising medication.
This principle has been little explored in people with intellectual
disability but has value in guiding decisions about psychotropic
drugs in other people.7 We should ensure that people with
intellectual disability act as partners in their care by enabling
access to relevant information and by developing tools that
support collaboration, such as tailored patient decision aids.
We must combine new approaches with generalisable knowledge
drawn from other populations and initiatives. For example, the
STOMP campaign has parallels with the national dementia
strategy, which substantially reduced prescribing of
antipsychotic drugs for adults with dementia over a relatively
short period,8 although people living in care homes—the most
vulnerable group—seem to have benefited less.9
Monitoring the effect of STOMP will therefore be essential and
is already part of the Royal College of Psychiatrists Centre for
Quality Improvement audit programme. Such audits provide
benchmarking data and direct future efforts.
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We need to invest in more research to clarify the role of
pharmacotherapy in the multimodal management of challenging
behaviour, with a focus on understanding the causes and
mediators of these behaviours and identifying subgroups of
people most likely to benefit from psychotropic drugs.
Qualitative investigation of the attitudes of patients, carers, and
clinicians to drug reductions, alongside explorations of contexts,
barriers, and facilitators will help to identify the complex
non-clinical and systems factors that influence use of
psychotropic drugs.
Changes in prescribing can be difficult to achieve, and the effect
of one-off policy interventions should not be overestimated.10
Meaningful and sustained change in psychotropic prescribing
requires a cultural shift in the way that people with intellectual
disability are supported by healthcare professionals and broader
society.
Other essential elements include commissioning the right care
in the right place, providing suitable educational and vocational
opportunities, and investing in early intervention and training
programmes for families and care staff. If we are serious about
improving use of psychotropic medication and valuing people
with intellectual disability we must ensure that a clear national
strategy combining policy drivers and much needed research
investment is prioritised to stop further disadvantage to this
patient group.
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